Skip to main content
Top
Published in: Current Treatment Options in Oncology 6/2015

01-06-2015 | Sarcoma (SH Okuno, Section Editor)

Preoperative Therapy for Extremity Soft Tissue Sarcomas

Authors: Lara E. Davis, M.D., Christopher W. Ryan, M.D.

Published in: Current Treatment Options in Oncology | Issue 6/2015

Login to get access

Opinion statement

High-risk soft tissue sarcomas (STS) are defined as large (>5 cm), intermediate/high-grade tumors and can carry a >50 % risk of death from metastases. A regimen of preoperative chemoradiation immediately addresses issues of both local control and micrometastases and should be considered for patients with high-risk STS of the extremities. While acute wound healing complications are more likely to occur, these are most always manageable and reversible, as opposed to the long-term complications associated with higher radiation doses and larger fields required for post-operative therapy. Preoperative treatment also yields potential prognostic information from pathologic treatment response, and quantitative imaging methods hold promise to detect early treatment effect. Definitive evidence of survival benefit from neoadjuvant therapy has been elusive, but a large body of experience has accumulated at dedicated centers where this approach is utilized. Whenever possible, it is imperative that patients with high-risk STS be enrolled on well-designed clinical trials. Treatment planning and administration requires a coordinated multidisciplinary approach that should be undertaken in high-volume centers with expertise in the management of sarcomas.
Literature
2.
go back to reference Suit HD, Russell WO, Martin RG. Sarcoma of soft tissue: clinical and histopathologic parameters and response to treatment. Cancer. 1975;35(5):1478–83.PubMedCrossRef Suit HD, Russell WO, Martin RG. Sarcoma of soft tissue: clinical and histopathologic parameters and response to treatment. Cancer. 1975;35(5):1478–83.PubMedCrossRef
3.
go back to reference Lindberg RD et al. Conservative surgery and postoperative radiotherapy in 300 adults with soft-tissue sarcomas. Cancer. 1981;47(10):2391–7.PubMedCrossRef Lindberg RD et al. Conservative surgery and postoperative radiotherapy in 300 adults with soft-tissue sarcomas. Cancer. 1981;47(10):2391–7.PubMedCrossRef
4.
go back to reference Yang JC et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol. 1998;16(1):197–203.PubMed Yang JC et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol. 1998;16(1):197–203.PubMed
5.
go back to reference Rosenberg SA et al. The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg. 1982;196(3):305–15.PubMedCentralPubMedCrossRef Rosenberg SA et al. The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg. 1982;196(3):305–15.PubMedCentralPubMedCrossRef
6.
go back to reference Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet. 1997;350(9092):1647–54. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet. 1997;350(9092):1647–54.
7.
go back to reference Weitz J, Antonescu CR, Brennan MF. Localized extremity soft tissue sarcoma: improved knowledge with unchanged survival over time. J Clin Oncol. 2003;21(14):2719–25.PubMedCrossRef Weitz J, Antonescu CR, Brennan MF. Localized extremity soft tissue sarcoma: improved knowledge with unchanged survival over time. J Clin Oncol. 2003;21(14):2719–25.PubMedCrossRef
8.••
go back to reference Woll PJ et al. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. Lancet Oncol. 2012;13(10):1045–54. This multicenter randomized trial of adjuvant doxorubicin/ifosfamide for resected STS found no survival benefit but includes an updated meta-analysis suggesting that patients with large, high-grade extremity sarcomas are most likely to benefit from chemotherapy.PubMedCrossRef Woll PJ et al. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. Lancet Oncol. 2012;13(10):1045–54. This multicenter randomized trial of adjuvant doxorubicin/ifosfamide for resected STS found no survival benefit but includes an updated meta-analysis suggesting that patients with large, high-grade extremity sarcomas are most likely to benefit from chemotherapy.PubMedCrossRef
9.
go back to reference Adjuvant chemotherapy for localised resectable soft tissue sarcoma in adults. Sarcoma Meta-analysis Collaboration (SMAC). Cochrane Database Syst Rev. 2000(2):CD001419. Adjuvant chemotherapy for localised resectable soft tissue sarcoma in adults. Sarcoma Meta-analysis Collaboration (SMAC). Cochrane Database Syst Rev. 2000(2):CD001419.
10.
go back to reference Pervaiz N et al. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer. 2008;113(3):573–81.PubMedCrossRef Pervaiz N et al. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer. 2008;113(3):573–81.PubMedCrossRef
11.
go back to reference O’Sullivan B et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet. 2002;359(9325):2235–41.PubMedCrossRef O’Sullivan B et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet. 2002;359(9325):2235–41.PubMedCrossRef
12.
go back to reference Davis AM et al. Late radiation morbidity following randomization to preoperative versus postoperative radiotherapy in extremity soft tissue sarcoma. Radiother Oncol. 2005;75(1):48–53.PubMedCrossRef Davis AM et al. Late radiation morbidity following randomization to preoperative versus postoperative radiotherapy in extremity soft tissue sarcoma. Radiother Oncol. 2005;75(1):48–53.PubMedCrossRef
13.
go back to reference Zagars GK et al. Preoperative vs. postoperative radiation therapy for soft tissue sarcoma: a retrospective comparative evaluation of disease outcome. Int J Radiat Oncol Biol Phys. 2003;56(2):482–8.PubMedCrossRef Zagars GK et al. Preoperative vs. postoperative radiation therapy for soft tissue sarcoma: a retrospective comparative evaluation of disease outcome. Int J Radiat Oncol Biol Phys. 2003;56(2):482–8.PubMedCrossRef
14.••
go back to reference Wang D, et al. Significant reduction of late toxicities in patients with extremity sarcoma treated with image-guided radiation therapy to a reduced target volume: results of Radiation Therapy Oncology Group RTOG-0630 Trial. J Clin Oncol. 2015. doi:10.1200/JCO.2014.58.5828. This multicenter prospective phase II trial identified a significant reduction in late toxicities in patients with extremity STS treated with preoperative radiotherapy without an increased local recurrences. Wang D, et al. Significant reduction of late toxicities in patients with extremity sarcoma treated with image-guided radiation therapy to a reduced target volume: results of Radiation Therapy Oncology Group RTOG-0630 Trial. J Clin Oncol. 2015. doi:10.​1200/​JCO.​2014.​58.​5828. This multicenter prospective phase II trial identified a significant reduction in late toxicities in patients with extremity STS treated with preoperative radiotherapy without an increased local recurrences.
15.
go back to reference Judson I, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 2014;15(4):415-423. Judson I, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 2014;15(4):415-423.
16.
go back to reference Antman KH et al. Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. J Clin Oncol. 1989;7(1):126–31.PubMed Antman KH et al. Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. J Clin Oncol. 1989;7(1):126–31.PubMed
17.
go back to reference O’Bryan RM et al. Phase II evaluation of adriamycin in human neoplasia. Cancer. 1973;32(1):1–8.PubMedCrossRef O’Bryan RM et al. Phase II evaluation of adriamycin in human neoplasia. Cancer. 1973;32(1):1–8.PubMedCrossRef
18.
go back to reference Bramwell VH et al. Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas. Eur J Cancer Clin Oncol. 1987;23(3):311–21.PubMedCrossRef Bramwell VH et al. Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas. Eur J Cancer Clin Oncol. 1987;23(3):311–21.PubMedCrossRef
19.
go back to reference Lorigan P et al. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol. 2007;25(21):3144–50.PubMedCrossRef Lorigan P et al. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol. 2007;25(21):3144–50.PubMedCrossRef
20.
go back to reference Gortzak E et al. A randomised phase II study on neo-adjuvant chemotherapy for ‘high-risk’ adult soft-tissue sarcoma. Eur J Cancer. 2001;37(9):1096–103.PubMedCrossRef Gortzak E et al. A randomised phase II study on neo-adjuvant chemotherapy for ‘high-risk’ adult soft-tissue sarcoma. Eur J Cancer. 2001;37(9):1096–103.PubMedCrossRef
21.
go back to reference Grobmyer SR et al. Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma. Ann Oncol. 2004;15(11):1667–72.PubMedCrossRef Grobmyer SR et al. Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma. Ann Oncol. 2004;15(11):1667–72.PubMedCrossRef
22.
go back to reference Eilber FR et al. Limb salvage for skeletal and soft tissue sarcomas. Multidisciplinary preoperative therapy. Cancer. 1984;53(12):2579–84.PubMedCrossRef Eilber FR et al. Limb salvage for skeletal and soft tissue sarcomas. Multidisciplinary preoperative therapy. Cancer. 1984;53(12):2579–84.PubMedCrossRef
23.
go back to reference Eilber F et al. Preoperative therapy for soft tissue sarcoma. Hematol Oncol Clin North Am. 1995;9(4):817–23.PubMed Eilber F et al. Preoperative therapy for soft tissue sarcoma. Hematol Oncol Clin North Am. 1995;9(4):817–23.PubMed
24.
go back to reference Edmonson JH et al. Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft tissue sarcomas: initial treatment with ifosfamide, mitomycin, doxorubicin, and cisplatin plus granulocyte macrophage-colony-stimulating factor. Cancer. 2002;94(3):786–92.PubMedCrossRef Edmonson JH et al. Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft tissue sarcomas: initial treatment with ifosfamide, mitomycin, doxorubicin, and cisplatin plus granulocyte macrophage-colony-stimulating factor. Cancer. 2002;94(3):786–92.PubMedCrossRef
25.
go back to reference DeLaney TF et al. Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas. Int J Radiat Oncol Biol Phys. 2003;56(4):1117–27.PubMedCrossRef DeLaney TF et al. Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas. Int J Radiat Oncol Biol Phys. 2003;56(4):1117–27.PubMedCrossRef
26.••
go back to reference Mullen JT et al. Long-term follow-up of patients treated with neoadjuvant chemotherapy and radiotherapy for large, extremity soft tissue sarcomas. Cancer. 2012;118(15):3758–65. With a median follow-up of over 9 years, a single institution’s regimen of preoperative MAID chemotherapy with interdigitated radiation resulted favorable survival compared to historic controls.PubMedCrossRef Mullen JT et al. Long-term follow-up of patients treated with neoadjuvant chemotherapy and radiotherapy for large, extremity soft tissue sarcomas. Cancer. 2012;118(15):3758–65. With a median follow-up of over 9 years, a single institution’s regimen of preoperative MAID chemotherapy with interdigitated radiation resulted favorable survival compared to historic controls.PubMedCrossRef
27.
go back to reference Pisters PW et al. Phase I trial of preoperative doxorubicin-based concurrent chemoradiation and surgical resection for localized extremity and body wall soft tissue sarcomas. J Clin Oncol. 2004;22(16):3375–80.PubMedCrossRef Pisters PW et al. Phase I trial of preoperative doxorubicin-based concurrent chemoradiation and surgical resection for localized extremity and body wall soft tissue sarcomas. J Clin Oncol. 2004;22(16):3375–80.PubMedCrossRef
28.
go back to reference Mack L et al. Preoperative chemoradiotherapy (modified Eilber protocol) provides maximum local control and minimal morbidity in patients with soft tissue sarcoma. Ann Surg Oncol. 2005;12(8):646–53.PubMedCrossRef Mack L et al. Preoperative chemoradiotherapy (modified Eilber protocol) provides maximum local control and minimal morbidity in patients with soft tissue sarcoma. Ann Surg Oncol. 2005;12(8):646–53.PubMedCrossRef
29.
go back to reference Ryan CW et al. Histologic response of dose-intense chemotherapy with preoperative hypofractionated radiotherapy for patients with high-risk soft tissue sarcomas. Cancer. 2008;112(11):2432–9.PubMedCrossRef Ryan CW et al. Histologic response of dose-intense chemotherapy with preoperative hypofractionated radiotherapy for patients with high-risk soft tissue sarcomas. Cancer. 2008;112(11):2432–9.PubMedCrossRef
30.
go back to reference Kraybill WG et al. Long-term results of a phase 2 study of neoadjuvant chemotherapy and radiotherapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall. Cancer. 2010;116(19):4613–21.PubMedCentralPubMedCrossRef Kraybill WG et al. Long-term results of a phase 2 study of neoadjuvant chemotherapy and radiotherapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall. Cancer. 2010;116(19):4613–21.PubMedCentralPubMedCrossRef
31.
go back to reference Hong NJL et al. Neoadjuvant chemoradiotherapy for patients with high-risk extremity and truncal sarcomas: a 10-year single institution retrospective study. Eur J Cancer. 2013;49(4):875–83.CrossRef Hong NJL et al. Neoadjuvant chemoradiotherapy for patients with high-risk extremity and truncal sarcomas: a 10-year single institution retrospective study. Eur J Cancer. 2013;49(4):875–83.CrossRef
32.•
go back to reference Meyer JM et al. Phase I trial of preoperative chemoradiation plus sorafenib for high-risk extremity soft tissue sarcomas with dynamic contrast-enhanced MRI correlates. Clin Cancer Res. 2013;19(24):6902–11. The addition of sorafenib 400 mg daily to a preoperative chemoradiation regimen was safe and effective, and DCE-MRI changes seen after 2 weeks of therapy correlated with histopathologic response at time of surgery.PubMedCrossRef Meyer JM et al. Phase I trial of preoperative chemoradiation plus sorafenib for high-risk extremity soft tissue sarcomas with dynamic contrast-enhanced MRI correlates. Clin Cancer Res. 2013;19(24):6902–11. The addition of sorafenib 400 mg daily to a preoperative chemoradiation regimen was safe and effective, and DCE-MRI changes seen after 2 weeks of therapy correlated with histopathologic response at time of surgery.PubMedCrossRef
33.
go back to reference Bedi M et al. Prognostic variables in patients with primary soft tissue sarcoma of the extremity and trunk treated with neoadjuvant radiotherapy or neoadjuvant sequential chemoradiotherapy. Radiat Oncol. 2013;8(1):60.PubMedCentralPubMedCrossRef Bedi M et al. Prognostic variables in patients with primary soft tissue sarcoma of the extremity and trunk treated with neoadjuvant radiotherapy or neoadjuvant sequential chemoradiotherapy. Radiat Oncol. 2013;8(1):60.PubMedCentralPubMedCrossRef
34.
go back to reference Raval RR, et al. Evaluating the role of interdigitated neoadjuvant chemotherapy and radiation in the management of high-grade soft-tissue sarcoma: the Johns Hopkins experience. Am J Clin Oncol. 2014. Raval RR, et al. Evaluating the role of interdigitated neoadjuvant chemotherapy and radiation in the management of high-grade soft-tissue sarcoma: the Johns Hopkins experience. Am J Clin Oncol. 2014.
35.
go back to reference Canter R et al. Phase I trial of neoadjuvant conformal radiotherapy plus Sorafenib for patients with locally advanced soft tissue sarcoma of the extremity. Ann Surg Oncol. 2014;21(5):1616–23.PubMedCentralPubMedCrossRef Canter R et al. Phase I trial of neoadjuvant conformal radiotherapy plus Sorafenib for patients with locally advanced soft tissue sarcoma of the extremity. Ann Surg Oncol. 2014;21(5):1616–23.PubMedCentralPubMedCrossRef
36.
go back to reference Lewin J et al. A phase Ib/II translational study of sunitinib with neoadjuvant radiotherapy in soft-tissue sarcoma. Br J Cancer. 2014;111(12):2254–61.PubMedCrossRef Lewin J et al. A phase Ib/II translational study of sunitinib with neoadjuvant radiotherapy in soft-tissue sarcoma. Br J Cancer. 2014;111(12):2254–61.PubMedCrossRef
37.
go back to reference Okuno SMD, et al. Chemotherapy, irradiation, and surgery for function-preserving curative therapy of primary extremity soft tissue sarcomas: initial treatment with I-MAP and inhalation GM-CSF during preoperative irradiation and postoperatively. Am J Clin Oncol. 2014. Okuno SMD, et al. Chemotherapy, irradiation, and surgery for function-preserving curative therapy of primary extremity soft tissue sarcomas: initial treatment with I-MAP and inhalation GM-CSF during preoperative irradiation and postoperatively. Am J Clin Oncol. 2014.
38.
go back to reference Hoekstra HJ et al. A combination of intraarterial chemotherapy, preoperative and postoperative radiotherapy, and surgery as limb-saving treatment of primarily unresectable high-grade soft tissue sarcomas of the extremities. Cancer. 1989;63(1):59–62.PubMedCrossRef Hoekstra HJ et al. A combination of intraarterial chemotherapy, preoperative and postoperative radiotherapy, and surgery as limb-saving treatment of primarily unresectable high-grade soft tissue sarcomas of the extremities. Cancer. 1989;63(1):59–62.PubMedCrossRef
39.
go back to reference Goodnight Jr JE et al. Limb-sparing surgery for extremity sarcomas after preoperative intraarterial doxorubicin and radiation therapy. Am J Surg. 1985;150(1):109–13.PubMedCrossRef Goodnight Jr JE et al. Limb-sparing surgery for extremity sarcomas after preoperative intraarterial doxorubicin and radiation therapy. Am J Surg. 1985;150(1):109–13.PubMedCrossRef
40.
go back to reference Denton JW et al. Preoperative regional chemotherapy and rapid-fraction irradiation for sarcomas of the soft tissue and bone. Surg Gynecol Obstet. 1984;158(6):545–51.PubMed Denton JW et al. Preoperative regional chemotherapy and rapid-fraction irradiation for sarcomas of the soft tissue and bone. Surg Gynecol Obstet. 1984;158(6):545–51.PubMed
41.
go back to reference Temple WJ et al. Neoadjuvant treatment in conservative surgery of peripheral sarcomas. Can J Surg. 1989;32(5):361–5.PubMed Temple WJ et al. Neoadjuvant treatment in conservative surgery of peripheral sarcomas. Can J Surg. 1989;32(5):361–5.PubMed
42.
go back to reference Wanebo HJ et al. Preoperative regional therapy for extremity sarcoma. A tricenter update. Cancer. 1995;75(9):2299–306.PubMedCrossRef Wanebo HJ et al. Preoperative regional therapy for extremity sarcoma. A tricenter update. Cancer. 1995;75(9):2299–306.PubMedCrossRef
43.
go back to reference Levine EA, Trippon M, Das Gupta TK. Preoperative multimodality treatment for soft tissue sarcomas. Cancer. 1993;71(11):3685–9.PubMedCrossRef Levine EA, Trippon M, Das Gupta TK. Preoperative multimodality treatment for soft tissue sarcomas. Cancer. 1993;71(11):3685–9.PubMedCrossRef
44.
go back to reference Eilber FR et al. Intravenous (IV) vs. intraarterial (IA) Adriamycin, 2800r radiation and surgical excision for extremity soft tissue sarcomas: a randomized prospective trial. Proc Am Soc Clin Oncol. 1990;9:309a. Eilber FR et al. Intravenous (IV) vs. intraarterial (IA) Adriamycin, 2800r radiation and surgical excision for extremity soft tissue sarcomas: a randomized prospective trial. Proc Am Soc Clin Oncol. 1990;9:309a.
45.
go back to reference Frustaci S et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol. 2001;19(5):1238–47.PubMed Frustaci S et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol. 2001;19(5):1238–47.PubMed
46.
go back to reference Eilber FC et al. Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas. J Clin Oncol. 2001;19(13):3203–9.PubMed Eilber FC et al. Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas. J Clin Oncol. 2001;19(13):3203–9.PubMed
47.
go back to reference MacDermed DM et al. Primary tumor necrosis predicts distant control in locally advanced soft-tissue sarcomas after preoperative concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2010;76(4):1147–53.PubMedCentralPubMedCrossRef MacDermed DM et al. Primary tumor necrosis predicts distant control in locally advanced soft-tissue sarcomas after preoperative concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2010;76(4):1147–53.PubMedCentralPubMedCrossRef
48.
go back to reference Andreou D et al. Prognostic relevance of the mitotic count and the amount of viable tumour after neoadjuvant chemotherapy for primary, localised, high-grade soft tissue sarcoma. Br J Cancer. 2015;112(3):455–60.PubMedCrossRef Andreou D et al. Prognostic relevance of the mitotic count and the amount of viable tumour after neoadjuvant chemotherapy for primary, localised, high-grade soft tissue sarcoma. Br J Cancer. 2015;112(3):455–60.PubMedCrossRef
49.
go back to reference Tateishi U et al. PET/CT allows stratification of responders to neoadjuvant chemotherapy for high-grade sarcoma: a prospective study. Clin Nucl Med. 2011;36(7):526–32.PubMedCrossRef Tateishi U et al. PET/CT allows stratification of responders to neoadjuvant chemotherapy for high-grade sarcoma: a prospective study. Clin Nucl Med. 2011;36(7):526–32.PubMedCrossRef
50.
go back to reference Vaynrub M et al. Prognostic value of necrosis after neoadjuvant therapy for soft tissue sarcoma. J Surg Oncol. 2015;111(2):152–7.PubMedCrossRef Vaynrub M et al. Prognostic value of necrosis after neoadjuvant therapy for soft tissue sarcoma. J Surg Oncol. 2015;111(2):152–7.PubMedCrossRef
51.•
go back to reference Mullen JT et al. Prognostic significance of treatment-induced pathologic necrosis in extremity and truncal soft tissue sarcoma after neoadjuvant chemoradiotherapy. Cancer. 2014;120(23):3676–82. Clinical outcomes for patients treated per single neoadjuvant chemoradiation protocol did not correlate with histopathologic response at time of surgery (≥95 % necrosis).PubMedCrossRef Mullen JT et al. Prognostic significance of treatment-induced pathologic necrosis in extremity and truncal soft tissue sarcoma after neoadjuvant chemoradiotherapy. Cancer. 2014;120(23):3676–82. Clinical outcomes for patients treated per single neoadjuvant chemoradiation protocol did not correlate with histopathologic response at time of surgery (≥95 % necrosis).PubMedCrossRef
52.
go back to reference Radiation therapy with or without combination chemotherapy or pazopanib hydrochloride before surgery in treating patients with newly diagnosed non-rhabdomyosarcoma soft tissue sarcomas that can be removed by Surgery (PAZNTIS). [cited 2015 March 3]; Available from: https://clinicaltrials.gov/ct2/show/NCT02180867. Radiation therapy with or without combination chemotherapy or pazopanib hydrochloride before surgery in treating patients with newly diagnosed non-rhabdomyosarcoma soft tissue sarcomas that can be removed by Surgery (PAZNTIS). [cited 2015 March 3]; Available from: https://​clinicaltrials.​gov/​ct2/​show/​NCT02180867.
53.
go back to reference Stacchiotti S et al. Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapy. Cancer. 2012;118(23):5857–66.PubMedCrossRef Stacchiotti S et al. Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapy. Cancer. 2012;118(23):5857–66.PubMedCrossRef
54.
go back to reference Canter RJ et al. Radiographic and histologic response to neoadjuvant radiotherapy in patients with soft tissue sarcoma. Ann Surg Oncol. 2010;17(10):2578–84.PubMedCentralPubMedCrossRef Canter RJ et al. Radiographic and histologic response to neoadjuvant radiotherapy in patients with soft tissue sarcoma. Ann Surg Oncol. 2010;17(10):2578–84.PubMedCentralPubMedCrossRef
55.
go back to reference Benz MR et al. FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas. Clin Cancer Res. 2009;15(8):2856–63.PubMedCentralPubMedCrossRef Benz MR et al. FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas. Clin Cancer Res. 2009;15(8):2856–63.PubMedCentralPubMedCrossRef
56.•
go back to reference Eary JF et al. Sarcoma mid-therapy [F-18]fluorodeoxyglucose positron emission tomography (FDG PET) and patient outcome. J Bone Joint Surg. 2014;96(2):152–8. A prospective trial found that change in FDG-avidity between baseline and after two cycles of preoperative chemotherapy added prognostic value to patient outcome predictions.PubMedCentralPubMedCrossRef Eary JF et al. Sarcoma mid-therapy [F-18]fluorodeoxyglucose positron emission tomography (FDG PET) and patient outcome. J Bone Joint Surg. 2014;96(2):152–8. A prospective trial found that change in FDG-avidity between baseline and after two cycles of preoperative chemotherapy added prognostic value to patient outcome predictions.PubMedCentralPubMedCrossRef
57.
go back to reference Wong P, et al. Combining targeted agents with modern radiotherapy in soft tissue sarcomas. J Natl Cancer Inst. 2014;106(11). Wong P, et al. Combining targeted agents with modern radiotherapy in soft tissue sarcomas. J Natl Cancer Inst. 2014;106(11).
58.
go back to reference Francis P et al. Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential. BMC Genomics. 2007;8:73.PubMedCentralPubMedCrossRef Francis P et al. Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential. BMC Genomics. 2007;8:73.PubMedCentralPubMedCrossRef
59.
go back to reference Rajendran JG et al. [(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression. Eur J Nucl Med Mol Imaging. 2003;30(5):695–704.PubMedCrossRef Rajendran JG et al. [(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression. Eur J Nucl Med Mol Imaging. 2003;30(5):695–704.PubMedCrossRef
60.
go back to reference van der Graaf WT et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379(9829):1879–86.PubMedCrossRef van der Graaf WT et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379(9829):1879–86.PubMedCrossRef
61.
go back to reference Lee H-J et al. Inhibition of vascular endothelial growth factor A and hypoxia-inducible factor 1α maximizes the effects of radiation in sarcoma mouse models through destruction of tumor vasculature. Int J Radiat Oncol Biol Phys. 2015;91(3):621–30.PubMedCrossRef Lee H-J et al. Inhibition of vascular endothelial growth factor A and hypoxia-inducible factor 1α maximizes the effects of radiation in sarcoma mouse models through destruction of tumor vasculature. Int J Radiat Oncol Biol Phys. 2015;91(3):621–30.PubMedCrossRef
62.
go back to reference Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307(5706):58–62.PubMedCrossRef Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307(5706):58–62.PubMedCrossRef
Metadata
Title
Preoperative Therapy for Extremity Soft Tissue Sarcomas
Authors
Lara E. Davis, M.D.
Christopher W. Ryan, M.D.
Publication date
01-06-2015
Publisher
Springer US
Published in
Current Treatment Options in Oncology / Issue 6/2015
Print ISSN: 1527-2729
Electronic ISSN: 1534-6277
DOI
https://doi.org/10.1007/s11864-015-0346-4

Other articles of this Issue 6/2015

Current Treatment Options in Oncology 6/2015 Go to the issue

Sarcoma (SH Okuno, Section Editor)

Immunotherapeutic Approaches to Sarcoma

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine